The Role of Pretherapy Quantitative Imaging and Dosimetry in Radioiodine Therapy for Advanced Thyroid Cancer
J. Taprogge(Royal Marsden Hospital), Glenn Flux(Royal Marsden NHS Foundation Trust), Jonathan Gear(Institute of Cancer Research), Kate Newbold(Royal Marsden NHS Foundation Trust), Rachel Phillip(University of Leeds), Rebecca Gregory(Barts Health NHS Trust), Gemma Ainsworth(University of Leeds), Francesca Leek(Royal Marsden NHS Foundation Trust), Amy B. Coulson(University of Leeds), Sarah Brown(University of Leeds), Yong Du(Royal Marsden Hospital), Carla Abreu(Royal Marsden NHS Foundation Trust), Jonathan Wadsley(Weston Park Cancer Centre), Siraj Yusuf(Royal Marsden NHS Foundation Trust), Iain Murray(Royal Marsden NHS Foundation Trust)
Cited by 19
Related Papers
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
|The Lancet Oncology|2019|1.2k
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
|The Lancet Oncology|2013|728
2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
|Thyroid|2021|699